I have a multidisciplinary background in pharmacy, epidemiology, and data science, and expertise in outcome-based health informatics and pharmacoepidemiology. My overarching research purpose is to develop a coordinated approach to accelerate real-world evidence using Big data to improve ageing and pioneer translational research to improve the safety of medicines in the ageing population.

As a member and key co-investigator within the Big Data and Better Ageing Research Group (along with Professor Philip Schluter and Associate Professor Hamish Jamieson (lead): https://www.otago.ac.nz/big-data-better-ageing/staff/index.html), my research has significantly impacted and advanced research in [a] improved understanding of the harmful effects of polypharmacy (application of drug burden index on big data) at a population-level, [b] quantifying multimorbidity (developed comorbidity index) in the ageing population, [c] using improved confounding methods for causal inference in observational studies, and more recently [d] using artificial intelligence to understanding clustering of multiple long-term conditions in the ageing population. In addition, my research has directly impacted patient care with a better understanding of the risks and benefits of using medicines in the ageing population.

I am interested to recruit doctoral students. Current projects on offer:

1. Development and validation of a novel anticholinergic tool to quantify anticholinergic burden.

2. Novel pharmacoepidemiological approaches to predict adverse drug reactions.

3. Measuring the impact of drug burden and polypharmacy on health outcomes in older people.

4. Artificial intelligence for identifying disease clusters in age-related multimorbidity.

5. Measuring the impact of the anticholinergic burden on health outcomes in individuals with dementia.